Schulman IRB, a central IRB in customer service and technology, launched its Central Neurology Review (CNR) service.
Through its partnership with the National Biomedical Research Ethics Council (NBREC), a Nevada-based 501(c) non-profit, Schulman developed CNR to assist research institutions and biopharma and device companies in navigating the latest developments in neurology research and human subject protections.
"As neurology research continues to evolve at a rapid rate, we saw the need to create a specialized IRB model that conducts neurology-focused scientific and regulatory review for multi-site studies," said Eli Alford, Schulman's chief operating officer. "Together with NBREC, we're excited to launch CNR and look forward to supporting the development of the latest techniques, methodologies and discoveries in neurology research."
CNR features a scientific review committee to complement Schulman's best-in-class IRB review. CNR is therapeutically focused and comprised of distinguished scientists and industry leaders who have experience conducting neurology research. By combining the robust expertise of a local IRB, the collaborative capabilities of a central IRB, and the leading minds in neurology research, CNR delivers independent, objective and authoritative review services.